BioInvent International Aktiebolag
Nasdaq Stockholm · LEI 549300E7QRHEF2IJUY10· Fiscal year 2025
Staff cost per employee
Not disclosed
Employees
Not disclosed
Quick read
- Revenue grew 406.9% year over year.
- Operating loss of $34.5M in 2025.
Last 3 years
Revenue
Operating income
See the share price on Google Finance ↗
Investor metrics
2025
- Operating margin
- -155.3%
- Net margin
- -147.0%
- ROE
- -59.7%
- Debt-to-equity
- 20.4%
- Equity ratio
- 83.1%